Navigation Links
The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
Date:10/4/2007

Free, Interactive Telephone Education Program Features Myeloma Experts,

Melissa Alsina, M.D. and Kathy A. Daily, R.N.

WHITE PLAINS, N.Y., Oct. 4 /PRNewswire/ -- Myeloma patients can learn about managing side effects during a free telephone education workshop sponsored by The Leukemia & Lymphoma Society, and led by myeloma experts Melissa Alsina, M.D., and Kathy A. Daily, R.N. of the H. Lee Moffitt Cancer & Research Institute.

"Managing Myeloma Side Effects: What you Need to Know," is scheduled for Wednesday, October 10, 2007, 12 noon -- 1:30 p.m. ET. Dr. Alsina, associate professor of medicine, for the bone marrow transplant program, and Kathy A. Daily, transplant nurse specialist, from the H. Lee Moffitt Cancer & Research Institute in Tampa, FL., will discuss diagnosis and treatment options of patients with myeloma, including information on emerging therapies under study. They will also discuss symptom and side effect management, information on the role of clinical trials and drug therapies in the advancement of myeloma treatment, and quality of life issues. A question-and-answer period will follow.

"The more information Myeloma patients have, the better decisions they can make in regard to treatment and side effect management," explains Robin Kornhaber, M.S.W., the Society's senior vice president of patient services. "We encourage patients, caregivers and healthcare providers to participate in this informative program."

This educational program is supported by Celgene and Millennium Pharmaceuticals. Nurses and social workers who participate in the program have an opportunity to earn 1.5 Continuing Education contact hours.

Registration

To register, call toll free by phone (866) 992-9950, ext. 304 or toll free by fax (888) 991-9951; email llsmyel@rmei.com (enter "Myeloma" in the subject field) or visit http://www.lls.org/myelomaeducation. Registrants will receive an information packet and toll free dial-in number within 7-10 days of signing up.

About Myeloma

Myeloma is a cancer of the plasma cells, a type of white blood cell found in many tissues of the body, but primarily in the bone marrow. In myeloma, a B lymphocyte, the cell that forms plasma cells, becomes malignant. It grows continuously and forms masses of plasma cells, especially in the marrow, destroying normal blood cell production.

Malignant plasma cells produce an abnormal protein called monoclonal immunoglobulin. Immunoglobulins (or antibodies) are an important part of the body's natural defense against infection because they recognize microbes that invade the body and permit then to be removed and destroyed. The onset of myeloma interferes with normal production of antibodies and makes myeloma patients susceptible to infections.

Often the first symptom of myeloma is bone pain caused by the effects of malignant plasma (myeloma) cells in the marrow. Patients may have anemia, tire more easily and feel weak. Fractures may occur as a result of the weakened bones. Recurrent infections may be an early sign of disease.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center staffed by Masters-level professionals who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. GLEEVEC - An Oral treatment for leukemia
2. GLEEVEC - An Oral treatment for leukemia
3. Looking Towards More Effective Leukemia Treatment
4. Cyclosporin A Treats Leukemia Complications
5. Exposure to EMF may cause leukemia
6. A new vaccine for leukemia
7. Leukemia pill shows promise against stomach cancer
8. Aspirin Lowers Leukemia Risk
9. Hope for Chemo-Resistant Leukemia Patients
10. Genes Found To Help Leukemia Treatment
11. Diet Found To Offer Protection Against Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... For the first time, International ... the exhibit floor for the 2017 HIMSS Conference & Exhibition at ... 2017, more than 40,000 healthcare industry professionals are expected at the conference, where ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's ... goals for each and every seminar, session and class she offers. At ... brainwave tools which help energize creativity, focus mental functions, enhance athletic focus and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... named a finalist in the 8th Annual DecisionHealth Platinum Awards in recognition of ... Qualis Health’s work is recognized across multiple award categories, highlighting four of the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will ... Trinity Health and the U.S. Soccer Foundation announced today that they have awarded ... Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting ... on all facets of clinical trial planning and management. Pharmica discussed the importance ... more. In addition, attendees stopping by Pharmica’s booth were able to demo its ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... today announced that executive management will participate in the ... February 22-23, 2017. Adrian Adams , Chief Executive ... 1:35 p.m. local time on Wednesday, February 22, 2017. ... the event may be accessed from the Investors section ...
(Date:2/16/2017)... REDWOOD CITY, Calif. , Feb. 16, 2017 ... ), a specialty pharmaceutical company focused on the ... treatment of moderate-to-severe acute pain, announced that ... executive officer and a member of the company,s ... Mr. Angotti brings over two decades of experience ...
(Date:2/16/2017)... 16, 2017 Research and Markets has announced ... Analysis & Trends - Function, Application, Cancer Type, Technology - Forecast ... ... Market is poised to grow at a CAGR of around 28.6% ... Some of the prominent trends that the ...
Breaking Medicine Technology: